Vor Biopharma Inc. Net Fee Amt
Vor Biopharma Inc. (VOR) had Net Fee Amt of $0 as of 2026-09-04, per its S-3ASR filed 2026-09-04.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-09-04
- 2026-09-04: Net Fee Amt $0.00.
- 2026-04-24: Net Fee Amt $11.39K.
| Period end | Net Fee Amt |
|---|---|
| 2026-09-04 | $0.00 S-3ASR · filed 2026-09-04 |
| 2026-04-24 | $11.39K S-3 · filed 2026-04-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |